Impact of DNA damage repair alterations on prostate cancer progression and metastasis.

Autor:	Lukashchuk N; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom., Barnicle A; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom., Adelman CA; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom., Armenia J; Oncology Data Science, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom., Kang J; Global Medicines Development, Oncology Research and Development (R&D), AstraZeneca, Gaithersburg, MD, United States., Barrett JC; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Waltham, MA, United States., Harrington EA; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Jun 26; Vol. 13, pp. 1162644. Date of Electronic Publication: 2023 Jun 26 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1162644
Abstrakt:	Prostate cancer is among the most common diseases worldwide. Despite recent progress with treatments, patients with advanced prostate cancer have poor outcomes and there is a high unmet need in this population. Understanding molecular determinants underlying prostate cancer and the aggressive phenotype of disease can help with design of better clinical trials and improve treatments for these patients. One of the pathways often altered in advanced prostate cancer is DNA damage response (DDR), including alterations in BRCA1/2 and other homologous recombination repair (HRR) genes. Alterations in the DDR pathway are particularly prevalent in metastatic prostate cancer. In this review, we summarise the prevalence of DDR alterations in primary and advanced prostate cancer and discuss the impact of alterations in the DDR pathway on aggressive disease phenotype, prognosis and the association of germline pathogenic alterations in DDR genes with risk of developing prostate cancer. Competing Interests: NL, AB, CA, JA, JK, JCB and EH are employees of, and hold stock at AstraZeneca. (Copyright © 2023 Lukashchuk, Barnicle, Adelman, Armenia, Kang, Barrett and Harrington.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu